Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA yield is N/A as of 2026-10-06T21:02:45.898Z.
Calculation as of: 2026-10-06T21:02:45.898Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 16c1118283d3d380e79e54cd720e88a66b4293c4936e446a72c17353f5d031e1
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
N/A
NeuroOne Medical Technologies Corporation
Market Cap
$9.83M
EBITDA Yield
N/A
| NAME | MARKET CAP | EBITDA YIELD |
|---|---|---|
| NeuroOne Medical Technologies Corporation (NMTC) | $9.83M | N/A |
| Valion Bio, Inc. (VBIO)vs › | $9.86M | N/A |
| MetaVia Inc. (MTVA)vs › | $9.75M | N/A |
| Satellos Bioscience Inc. (MSLE)vs › | $9.71M | N/A |
| Medicus Pharma Ltd. Common Stock (MDCX)vs › | $10.06M | N/A |
| Senti Biosciences, Inc. (SNTI)vs › | $10.06M | N/A |
| Tvardi Therapeutics, Inc. (TVRD)vs › | $10.13M | N/A |
| Ainos, Inc. (AIMD)vs › | $9.50M | N/A |
| Lifeward Ltd. (LFWD)vs › | $10.21M | N/A |
| Adial Pharmaceuticals, Inc. (ADIL)vs › | $10.45M | N/A |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
